GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,075,177 shares, an increase of 243.3% from the April 30th total of 604,557 shares. Currently, 6.0% of the company’s shares are short sold. Based on an average daily trading volume, of 2,320,983 shares, the short-interest ratio is currently 0.9 days.

Hedge Funds Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new position in GT Biopharma, Inc. (NASDAQ:GTBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned approximately 0.47% of GT Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 8.15% of the company’s stock.

GT Biopharma Price Performance

NASDAQ GTBP traded up $0.04 during trading on Friday, reaching $0.48. 2,059,462 shares of the company’s stock traded hands, compared to its average volume of 1,254,953. The company’s 50 day simple moving average is $0.39 and its two-hundred day simple moving average is $0.55. GT Biopharma has a 12-month low of $0.26 and a 12-month high of $3.85. The firm has a market cap of $17.42 million, a price-to-earnings ratio of -0.08 and a beta of 0.64.

GT Biopharma (NASDAQ:GTBP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Research analysts expect that GT Biopharma will post -0.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a research note on Friday, April 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).